Dalfampridine

Generic Name: Dalfampridine

Brand Names: Ampyra, Fampyra, Fampridine Accord

Drug Type: Small Molecule

Chemical Formula: C_₅H_₆N_₂

CAS Number: 504-24-5

Unique Ingredient Identifier: BH3B64OKL9

Background: Dalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients. FDA approved on January 22, 2010.

Indication: Dalfampridine is a neurofunctional modifier that helps improve walking speed in patients with multiple sclerosis (MS).

Associated Conditions: Multiple Sclerosis

Clinical Trials

Double Dose 4-AP on Functional Recovery After Spinal Cord Injury

Phase 1

Recruiting

Conditions: SCI - Spinal Cord Injury

Interventions: Drug: Dalfampridine
Drug: Placebo
Other: STDP stimulation
Behavioral: Exercise training

First Posted Date: 2025-03-25

Last Posted Date: 2025-04-03

Lead Sponsor: Shirley Ryan AbilityLab

Target Recruit Count: 27

Registration Number: NCT06853015

Locations: 🇺🇸
Shirley Ryan Abilitylab, Chicago, Illinois, United States

Cross-over Study on the Influence of Fampridine on Working Memory in Mild Depression

Phase 2

Not yet recruiting

Conditions: Working Memory
Mild Depression

Interventions: Other: Placebo
Drug: Fampridine SR

First Posted Date: 2024-12-30

Last Posted Date: 2025-01-08

Lead Sponsor: University of Basel

Target Recruit Count: 38

Registration Number: NCT06751784

Locations: 🇨🇭
University of Basel, Reserach Cluster Molecular and Cognitive Neurosciences, Basel, BS, Switzerland

4-Aminopyridine to Treat Skin Burns

Phase 2

Not yet recruiting

Conditions: Burns
Second Degree Burn
Wounds and Injuries

Interventions: Other: Placebo

First Posted Date: 2024-09-19

Last Posted Date: 2025-05-04

Lead Sponsor: John Elfar

Target Recruit Count: 200

Registration Number: NCT06596434

Locations: 🇺🇸
University of Arizona, Tucson, Arizona, United States

4-aminopyridine for Skin Wound Healing

Phase 2

Not yet recruiting

Conditions: Wounds
Wound of Skin
Wounds and Injuries
Wound Heal

Interventions: Other: Placebo
Drug: 4-Aminopyridine

First Posted Date: 2024-03-27

Last Posted Date: 2025-05-04

Lead Sponsor: John Elfar

Target Recruit Count: 150

Registration Number: NCT06333171

Locations: 🇺🇸
University of Arizona, Tucson, Arizona, United States

4AP to Delay Carpal Tunnel Release (CTR)

Phase 2

Not yet recruiting

Conditions: Carpal Tunnel Syndrome
Compression Neuropathy

Interventions: Drug: 4-Aminopyridine
Other: Placebo

First Posted Date: 2024-03-06

Last Posted Date: 2025-05-04

Lead Sponsor: John Elfar

Target Recruit Count: 160

Registration Number: NCT06294821

Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis

Phase 4

Recruiting

Conditions: Multiple Sclerosis

Interventions: Behavioral: Physical therapy
Drug: Dalfampridine 10 MG [Ampyra]
Other: Dalfampridine plus physical therapy

First Posted Date: 2023-11-18

Last Posted Date: 2024-12-19

Lead Sponsor: MGH Institute of Health Professions

Target Recruit Count: 48

Registration Number: NCT06136728

Locations: 🇺🇸
MGH Institute of Health Professions, Boston, Massachusetts, United States

4-AP Peripheral Nerve Crossover Trial

Phase 2

Recruiting

Conditions: Crush Injury
Peripheral Nerve Injury

Interventions: Drug: 4-Aminopyridine
Other: Placebo

First Posted Date: 2023-08-21

Last Posted Date: 2025-05-04

Lead Sponsor: University of Arizona

Target Recruit Count: 68

Registration Number: NCT06003166

Locations: 🇺🇸
Banner University Medical Center, Tucson, Arizona, United States

Effects of Physical Therapy and Dalfampridine on Functional Mobility in Non Ambulatory Persons With Multiple Sclerosis

Phase 2

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Dalfampridine Pill
Drug: Placebo

First Posted Date: 2023-05-16

Last Posted Date: 2023-05-16

Lead Sponsor: D'Youville College

Target Recruit Count: 35

Registration Number: NCT05859802

Dalfampridine in Egyptian Patients With Multiple Sclerosis

Not Applicable

Recruiting

Conditions: Multiple Sclerosis

Interventions: Drug: Dalfampridine ER, 10 Mg Oral Tablet, Extended Release
Drug: Placebo

First Posted Date: 2023-02-16

Last Posted Date: 2023-02-16

Lead Sponsor: Ain Shams University

Target Recruit Count: 100

Registration Number: NCT05730738

Locations: 🇪🇬
Ain Shams Univeristy, Cairo, Egypt

Effect of Dalfampridine in Patients With Hereditary Spastic Paraplegia

Not Applicable

Completed

Conditions: Hereditary Spastic Paraplegia

Interventions: Drug: Dalfampridine 10 MG
Drug: Placebo
Behavioral: Physiotherapy

First Posted Date: 2022-11-14

Last Posted Date: 2022-11-22

Lead Sponsor: European University of Lefke

Target Recruit Count: 8

Registration Number: NCT05613114

Locations: 🇨🇾
Dr. Burhan Nalbantoğlu State Hospital, Nicosia, Cyprus

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy